Orion OYJ (ORINY) Stock Price, News & Analysis

Company Overview

Orion Oyj is a Finland-based pharmaceutical company headquartered in Espoo, with roots tracing back to its founding in 1917 by pharmacist Onni Turpeinen. Under the leadership of President and CEO Timo Lappalainen, the company operates through its core Pharmaceuticals segment, focusing on both human and veterinary medicines, and maintains a global footprint across Europe, Russia, Asia and select emerging markets. Orion’s manufacturing network is centered in Espoo and Kuopio, bolstered by sales offices in key regions to support its international distribution.

The company’s human pharmaceuticals portfolio spans a range of therapeutic areas, including central nervous system disorders, oncology, cardiovascular disease and Parkinson’s disease. Signature products include Simdax (levosimendan) for acute heart failure, Dexdor (dexmedetomidine) for intensive care sedation, and Stalevo (carbidopa/levodopa/entacapone) for Parkinson’s disease, developed in collaboration with global partners. Orion also markets veterinary formulations and offers specialty care medicines tailored to animal health.

Historically, Orion operated a Diagnostics division that produced reagents and point-of-care tests for blood group serology and hemostasis, helping to strengthen its presence in clinical diagnostics. Although the company has refocused its operations more squarely on pharmaceuticals and drug development, it continues to leverage its legacy of diagnostic expertise through research collaborations and contract manufacturing arrangements in the wider life-science sector.

A cornerstone of Orion’s strategy is its commitment to research and development. The company invests in early-stage and late-stage clinical programs, maintaining strategic partnerships with academic institutions and biotech firms. This R&D focus underpins Orion’s pipeline of novel therapeutics and generics alike, aimed at addressing unmet medical needs and expanding its portfolio through both in-house innovation and external collaborations.

Key Stats

• Today's Range: $37.81 to $37.81
• 50-Day Range: $29.10 to $37.53
• 52-Week Range: $21.10 to $37.81
• Volume: 122 shs
• Average Volume: 1,947 shs
• Market Capitalization: $10.67 billion
• P/E Ratio: 28.86
• Dividend Yield: 0.85%
• Price Target: N/A
• Consensus Rating: Hold

ORINY Stock Analysis - Frequently Asked Questions

How have ORINY shares performed this year?

Orion OYJ's stock was trading at $21.95 at the beginning of 2025. Since then, ORINY stock has increased by 72.3% and is now trading at $37.81.

How were Orion OYJ's earnings last quarter?

Orion OYJ Unsponsored ADR (OTCMKTS:ORINY) announced its earnings results on Wednesday, April, 23rd. The company reported $0.23 earnings per share for the quarter. The firm had revenue of $373.03 million for the quarter. Orion OYJ had a trailing twelve-month return on equity of 36.23% and a net margin of 21.74%.

How do I buy shares of Orion OYJ?

Shares of ORINY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Record date for 4/29 Dividend: 4/07/2025
• Ex-Dividend for 4/29 Dividend: 4/07/2025
• Last Earnings: 4/23/2025
• Dividend Payable: 4/29/2025
• Today: 7/08/2025
• Next Earnings (Estimated): 7/18/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:ORINY
• Previous Symbol: NASDAQ:ORINY
• CIK: N/A
• Web: www.orion.fi
• Phone: 358 10 4261
• Fax: N/A
• Employees: 3,712
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): $1.31
• Trailing P/E Ratio: 28.86
• Forward P/E Ratio: 32.04
• P/E Growth: N/A
• Net Income: $356.98 million
• Net Margins: 21.74%
• Pretax Margin: 27.77%
• Return on Equity: 36.23%
• Return on Assets: 21.28%

Debt

• Debt-to-Equity Ratio: 0.27
• Current Ratio: 3.79
• Quick Ratio: 2.27

Sales & Book Value

• Annual Sales: $1.67 billion
• Price / Sales: 6.39
• Cash Flow: $1.65 per share
• Price / Cash Flow: 22.94
• Book Value: $3.85 per share
• Price / Book: 9.82

Miscellaneous

• Outstanding Shares: 282,270,000
• Free Float: N/A
• Market Cap: $10.67 billion
• Optionable: Not Optionable
• Beta: 0.10